ECLIPSE: J&J's Tremfya Beats Novartis' Cosentyx For Long-Term Psoriasis Clearance

 
• By Emily Hayes

Novartis stresses long-term safety database for Cosentyx – with five years' worth of data in three indications – psoriasis, psoriatic arthritis and ankylosing spondylitis.

Solar Eclipse "Elements of this image furnished by NASA "

More from Clinical Trials

More from R&D